All Stories

Biogen axes asset from $7.3B buyout, along with Alzheim...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired i...

Judge puts nationwide hold on NIH grant change after un...

A federal judge has issued a temporary pause across all states on the new NIH or...

Judge places NIH grant initiative on hold nationwide af...

A federal judge has issued a temporary pause across all states on the new NIH or...

AbbVie signs heavily backloaded $2.1B Xilio biobucks pa...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to th...

Sanofi-backed Abcuro raises $200M series C to fund pivo...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its ant...

Biogen enlists Royalty for pursuit of lupus crown, secu...

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharm...

GSK plans to move vaccine R&D center from Rockville, Ma...

After calling Rockville, Maryland, home for more than eight years, pharma giant ...

GSK plans to move vaccine R&D center from Rockville, Ma...

After calling Rockville, Maryland home for more than eight years, pharma giant G...

GSK plans to move vaccine R&D center from Rockville, Md...

After calling Rockville, Maryland home for more than eight years, pharma giant G...

Inspire Medical discloses DOJ civil false claims invest...

The neurostimulation company, based outside Minneapolis, said in a filing that i...

Pfizer's investigational candidate combo cuts prostate ...

After an apparent accidental early release, Pfizer has revealed phase 1 data sho...

Pfizer’s investigational candidate combo cuts prostate ...

After an apparent accidental early release, Pfizer has revealed phase 1 data sho...

Journey of Voyager’s ALS gene therapy to clinic hindere...

Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis...

Fierce Biotech Layoff Tracker 2025: Inventiva and Third...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Third Harmonic halves headcount to take urticaria drug ...

Third Harmonic Bio will lay off half of its workforce, the biotech has said as i...

UPDATE: Judge temporarily blocks NIH grant changes in 2...

A new initiative rolled out under President Donald Trump’s administration is cut...

Insilico Medicine provides benchmark timelines from its...

Insilico also disclosed it’s begun chasing new therapeutic areas in obesity and ...

Incyte exits immuno-oncology pact, leaving Agenus weigh...

Incyte has broken off its immuno-oncology deal with Agenus. The step, which foll...

Inventiva lays off 50% of staff to go all-in on MASH drug

Inventiva is going all-in on its metabolic-associated steatohepatitis drug lanif...

Q32 Bio sticks with bempikibart but loses staff and pha...

Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikib...

Novartis inks $925M Anthos takeover to buy back phase 3...

Novartis has brought abelacimab back into the fold. Six years after spinning the...

Q32 Bio sticks with bempikibart, but loses staff and ph...

Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikib...

Fierce Biotech Layoff Tracker 2025: Q32 Bio restructure...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Tasso rolls out new at-home dried blood spot sample col...

Its Tile-T20 cartridge and the wearable Tasso Mini push-button lancet are design...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.